2024-03-29T12:07:02Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/65352022-11-03T15:05:08Zcom_20.500.12105_2145com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2146
00925njm 22002777a 4500
dc
Jimenez-Lucena, Rosa
author
Alberto Rangel-Zuniga, Oriol
author
Alcala-Diaz, Juan Francisco
author
Lopez-Moreno, Javier
author
Roncero-Ramos, Irene
author
Molina-Abril, Helena
author
Maria Yubero-Serrano, Elena
author
Caballero-Villarraso, Javier
author
Delgado-Lista, Javier
author
Pastor Castano, Justo
author
Ordovas, Jose M
author
Perez-Martinez, Pablo
author
Camargo, Antonio
author
Lopez-Miranda, Jose
author
2018
Circulating microRNAs (miRNAs) have been proposed as type 2 diabetes biomarkers, and they may be a more sensitive way to predict development of the disease than the currently used tools. Our aim was to identify whether circulating miRNAs, added to clinical and biochemical markers, yielded better potential for predicting type 2 diabetes. The study included 462 non-diabetic patients at baseline in the CORDIOPREV study. After a median follow-up of 60 months, 107 of them developed type 2 diabetes. Plasma levels of 24 miRNAs were measured at baseline by qRT-PCR, and other strong biomarkers to predict diabetes were determined. The ROC analysis identified 9 miRNAs, which, added to HbA1c, have a greater predictive value in early diagnosis of type 2 diabetes (AUC = 0.8342) than HbA1c alone (AUC = 0.6950). The miRNA and HbA1c-based model did not improve when the FINDRISC was included (AUC = 0.8293). Cox regression analyses showed that patients with low miR-103, miR-28-3p, miR-29a, and miR-9 and high miR-30a-5p and miR-150 circulating levels have a higher risk of disease (HR = 11.27; 95\% CI = 2.61-48.65). Our results suggest that circulating miRNAs could potentially be used as a new tool for predicting the development of type 2 diabetes in clinical practice.
Mol Ther Nucleic Acids. 2018; 12:146-157
2162-2531
http://hdl.handle.net/20.500.12105/6535
30195754
10.1016/j.omtn.2018.05.002
Molecular Therapy - Nucleic Acids
PANCREATIC BETA-CELLS
INSULIN-RESISTANCE
CARDIOVASCULAR-DISEASE
CLINICAL-TRIAL
MICRORNAS
RISK
SENSITIVITY
EXPRESSION
METABOLOMICS
REVEALS
Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary HeartDisease Patients from the CORDIOPREV Study